Iridex (Mountain View, CA) has received CE Mark regulatory approval in Europe for its G-Probe Illuminate probe, which combines transillumination and a laser fiber for targeted transscleral cyclophotocoagulation (CPC; a glaucoma treatment). The probe, which received FDA clearance and was launched in early 2017, is powered by the company's Cyclo G6 glaucoma laser system. The system features built-in transillumination to optimize placement of the probe and therapeutic outcomes.
Related: Iridex ophthalmic laser system for glaucoma treatment receives CE Mark approval
Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia, and post-corneal transplants generate even more challenges. The G-Probe Illuminate may improve the ability of physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.
The G-Probe Illuminate may be used in the operating room or as an outpatient, office-based procedure for treating glaucoma.
For more information, please visit www.iridex.com.